Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction

NCT04703842 is registered in ClinicalTrials.gov with Sardocor Corp. as lead sponsor.

NCT NCT04703842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04703842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction
Lead sponsor
Sardocor Corp.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 23, 2021
Completion date
December 31, 2028
Enrollment
57 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

congestive heart failure, heart failure, heart failure, systolic, hfref - heart failure with reduced ejection fraction